Search research articles
Contact Us
Filters
Showing results (111-120 of 197) with videos related to
Page
of 20
Sort By:
Annals of Emergency Medicine
|
March 20, 2012
An overview of the adaptive designs accelerating promising trials into treatments (ADAPT-IT) project
William J Meurer, Roger J Lewis, Danilo Tagle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 28, 2009
Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013
Lyndsay N Harris, Gloria Broadwater, Maysa Abu-Khalaf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2002
BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes
Donald A Berry, Edwin S Iversen, Daniel F Gudbjartsson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 17, 2008
Flawed inferences about screening mammography's benefit based on observational data
Donald A Berry, Cornelia J Baines, Michael Baum, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 9, 2008
Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B
Michael P DiGiovanna, David F Stern, Susan Edgerton, et al.
Breast (Edinburgh, Scotland)
|
October 22, 2011
Modeling the impact of population screening on breast cancer mortality in the United States
Jeanne S Mandelblatt, Kathleen A Cronin, Donald A Berry, et al.
Leukemia & Lymphoma
|
July 11, 2022
PET-CR as a potential surrogate endpoint in untreated DLBCL: meta-analysis and implications for clinical trial design
Kristine Broglio, Lale Kostakoglu, Carol Ward, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 25, 2012
Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101
Lawrence N Shulman, Constance T Cirrincione, Donald A Berry, et al.
Alzheimer'S Research & Therapy
|
May 21, 2022
Correction to: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody
Chad J Swanson, Yong Zhang, Shobha Dhadda, et al.
Alzheimer'S Research & Therapy
|
April 18, 2021
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody
Chad J Swanson, Yong Zhang, Shobha Dhadda, et al.
Page
of 20
Search research articles
Search
Showing results (111-120 of 197) with videos related to
Sort By:
Page
of 20
Annals of Emergency Medicine
|
March 20, 2012
An overview of the adaptive designs accelerating promising trials into treatments (ADAPT-IT) project
William J Meurer, Roger J Lewis, Danilo Tagle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 28, 2009
Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013
Lyndsay N Harris, Gloria Broadwater, Maysa Abu-Khalaf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2002
BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes
Donald A Berry, Edwin S Iversen, Daniel F Gudbjartsson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 17, 2008
Flawed inferences about screening mammography's benefit based on observational data
Donald A Berry, Cornelia J Baines, Michael Baum, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 9, 2008
Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B
Michael P DiGiovanna, David F Stern, Susan Edgerton, et al.
Breast (Edinburgh, Scotland)
|
October 22, 2011
Modeling the impact of population screening on breast cancer mortality in the United States
Jeanne S Mandelblatt, Kathleen A Cronin, Donald A Berry, et al.
Leukemia & Lymphoma
|
July 11, 2022
PET-CR as a potential surrogate endpoint in untreated DLBCL: meta-analysis and implications for clinical trial design
Kristine Broglio, Lale Kostakoglu, Carol Ward, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 25, 2012
Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101
Lawrence N Shulman, Constance T Cirrincione, Donald A Berry, et al.
Alzheimer'S Research & Therapy
|
May 21, 2022
Correction to: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody
Chad J Swanson, Yong Zhang, Shobha Dhadda, et al.
Alzheimer'S Research & Therapy
|
April 18, 2021
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody
Chad J Swanson, Yong Zhang, Shobha Dhadda, et al.
Page
of 20